Article

A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant

2021-12-27

Abstract excerpt

Although efficacious vaccines have significantly reduced the morbidity and mortality due to COVID-19, there remains an unmet medical need for treatment options, which monoclonal antibodies (mAbs) can potentially fill. This unmet need is exacerbated by the emergence and spread of SARS-CoV-2 variants of concern (VOCs) that have shown some resistance to vaccine responses. Here we report the isolation of two highly po...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: de45ac70-43d2-5b8c-b31a-0ae8ad4e04d8
DOI: 10.1101/2021.12.25.474152

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variantDOI 10.1101/2021.12.25.474152Read

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.Semantic proximity Read

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsSemantic proximity Read

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsSemantic proximity Read

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccinesSemantic proximity Read

Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patientsSemantic proximity Read

Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal AntibodiesSemantic proximity Read

Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responsesSemantic proximity Read

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity Read